Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 6/2013

01.12.2013 | Central Nervous System (J Lyons, Section Editor)

Neurological Complications in Controlled HIV Infection

verfasst von: Kate M. Crossley, Bruce J. Brew

Erschienen in: Current Infectious Disease Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

In recent years, there have been great advances in therapies for human immunodeficiency virus (HIV) that have allowed suppression of the virus and its effects on the body. Despite this progress, neurological complications persist in HIV-infected individuals. In this review we consider the possible ways that HIV might cause neurotoxicity and neuroinflammation. We discuss the spectrum of neurological disorders caused by HIV and its treatment, with a particular focus on both HIV-associated neurocognitive disorders and peripheral neuropathies. Since there has been a shift to HIV being a chronic illness, we also review the increasing prevalence of cerebrovascular disease and neurodegenerative disorders.
Literatur
1.
del Palacio M, Álvarez S, Muñoz-Fernández MA. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol. 2012;22:33–45.PubMedCrossRef
2.
•• Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011;17:176–83. A study of a cohort of advanced HIV+ individuals on cART that found that despite suppression of systemic viral load, HIV-related neuropsychological impairment prevalence reached 18.1%.PubMedCrossRef
3.
4.
• Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148. A meta-review that found that neuroHAART improves neurocognitive function and suppresses CSF HIV RNA.PubMedCrossRef
5.
Mirza A, Rathore MH. Human immunodeficiency virus and the central nervous system. Semin Pediatr Neurol. 2012;19:119–23.PubMedCrossRef
6.
Kraft-Terry SD et al. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37:542–8.PubMedCrossRef
7.
• Peluso MJ et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765–74. Retrospective case series of 10 HIV-infected patients who presented with neurological symptoms and were shown to have CSF "escape" of virus.PubMedCrossRef
8.
Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis. 2010;50:930–2.PubMedCrossRef
9.
Liner KJ, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep. 2010;7:85–91.PubMedCrossRef
10.
• Desplats P et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013;80:1415–23. A case–control study of the neuropathologic and molecular findings in patients with latent CNS HIV-1 infection that found an association with increased levels of chromatin modifiers, including BCL11B.PubMedCrossRef
11.
Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res. 2012;21:79–89.PubMedCrossRef
12.
Jaeger LB, Nath A. Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Dis Models Mech. 2012;5:313–22.CrossRef
13.
14.
Brew BJ et al. The neurological features of early and 'latent' human immunodeficiency virus infection. Aust NZ J Med. 1989;19:700–5.CrossRef
15.
Antinori A, Arendt G, Becker JT. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99.PubMedCrossRef
16.
Garvey L et al. Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease. Neurology. 2011;76:693–700.PubMedCrossRef
17.
Heaton RK et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurology. 2010;75:2087–96.PubMedCrossRef
18.
• Ciccarelli N et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV infected patients. Neurology. 2011;76:1403–9. A cross-sectional single-cohort study that found an association between HAND and efavirenz use.PubMedCrossRef
19.
Brew BJ, et al. Neurodegeneration and ageing in the HAART Era. J Neuroimmune Pharm. 2009;4(2):163–74
20.
Yao H et al. HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharm. 2010;5:489–95.CrossRef
21.
• Kallianpur KJ et al. Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter. Neurology. 2013;80:1792–9. A cross-sectional study that used MRI and MR spectroscopy to demonstrate an association between regional brain atrophy and persistance of HIV DNA in the peripheral blood.PubMedCrossRef
22.
Andersen ÅB et al. Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation. 2010;7:13.PubMedCrossRef
23.
Gannon P, Khana MZ, Kolsona DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24:275–83.PubMedCrossRef
24.
Mothobia NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25:4–9.CrossRef
25.
Johnson T, Nath A. Immune reconstitution inflammatory system and the central nervous system. Curr Opin Neurol. 2011;24:284–90.PubMedCrossRef
26.
Cysique LAJ, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447–50.PubMedCrossRef
27.
Tan IL, McArthur JC. HIV-associated neurological disorders a guide to pharmacotherapy. CNS Drugs. 2012;26(2):123–34.PubMedCrossRef
28.
Rackstraw S. HIV-related neurocognitive impairment – a review. Psychol, Health Med. 2011;16(5):548–63.CrossRef
29.
Thien H et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med. 2007;8:520–8.CrossRef
30.
McPhail ME, Robertson KR. Neurocognitive impact of antiretroviral treatment: thinking long-term. Curr HIV/AIDS Rep. 2011;8:249–56.PubMedCrossRef
31.
Clifford DB et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73:309–14.PubMedCrossRef
32.
Lindl KA et al. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharm. 2010;5:294–309.CrossRef
33.
• Ellisa RJ et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747–51. A large observational study that showed the risk of neuropsychological impairment was lowest in patients without a low CD4 nadir pre-CART initiation.CrossRef
34.
Letendre SL. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19(4):137–42.PubMed
35.
•• The Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56(7):1004–17. Evidence-based consensus statement from international experts to guide the diagnosis, monitoring, and treatment of HAND.CrossRef
36.
•• Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol. 2013;12:295–309. A review of the clinical presentation, causes, and management of peripheral neuropathies in HIV-infected patients.PubMedCrossRef
37.
Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review. AIDS Res Hum Retrovir. 2012;28(1):36–48.PubMedCrossRef
38.
Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep. 2012;16:226–36.PubMedCrossRef
39.
Ng K et al. Axonal excitability in viral polyneuropathy and nucleoside neuropathy in HIV patients. J Neurol Neurosurg Psychiatry. 2011;82:978–80.PubMedCrossRef
40.
Cherry CL et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006;66:867–73.PubMedCrossRef
41.
Cruse B et al. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol. 2012;18:264–76.PubMedCrossRef
42.
Benjamin LA et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11:878–90.PubMedCrossRef
43.
Sen S et al. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis. 2012;33:209–18.PubMedCrossRef
44.
Brew BJ et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65:1490–2.PubMedCrossRef
45.
Birbeck GL et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS. Neurology. 2012;78:139–45.PubMedCrossRef
46.
• Heinze B, Swanepoel DW, Hofmeyr LM. Systematic review of vestibular disorders related to human immunodeficiency virus and acquired immunodeficiency syndrome. J Laryngol Otol. 2011;125:881–90. Guidelines for the selection of antiepileptic drugs among people with HIV/AIDS.PubMedCrossRef
47.
Brew BJ. HIV neurology. Oxford University Press; 2001.
Metadaten
Titel
Neurological Complications in Controlled HIV Infection
verfasst von
Kate M. Crossley
Bruce J. Brew
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 6/2013
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0375-8

Weitere Artikel der Ausgabe 6/2013

Current Infectious Disease Reports 6/2013 Zur Ausgabe

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Infectious Complications of Immune Modulatory Agents

Invited Commentary

Does the Nose Know? An Update on MRSA Decolonization Strategies

CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)

Central Nervous System Infections in Travelers

Healthcare Associated Infections (G Bearman and M Stevens, Section Editors)

Positive Deviance: A New Tool for Infection Prevention and Patient Safety

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Influenza Vaccination in Oncology Patients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise